AstraZeneca's Evusheld (tixagevimab and cilgavimab) Receives EC’s Approval for the Treatment of COVID-19
Shots:
- The EC has approved Evusheld in adults & adolescents aged ≥12yrs. with COVID‑19 who do not require supplemental oxygen & with a high risk of progressing to sev. COVID‑19
- The approval was based on the P-III (TACKLE) trial evaluating Evusheld (300mg each, IM) vs PBO in a ratio (1:1) in 903 patients with COVID-19 who were symptomatic for ≤7 days
- The results showed that 1 IM dose of Evusheld provides protection against progression to sev. COVID-19 or death from any cause, 90% were at high risk due to co-morbidities or age, 50% reduction in relative risk of progressing to sev. COVID-19 or death @29 Days in non-hospitalized patients; risk reduction (88% & 67%) within 3 & 5 days of symptom onset in pre-specified analyses, was well tolerated
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
